Genkyotex Pulls in $26M to Advance Its NOX Inhibitor
By Nuala Moran
Wednesday, July 11, 2012
LONDON Genkyotex SA has raised CHF25 million (US$26 million) as an extension to its Series C, with the existing investors all following on to fund Phase II development of the lead compound, GKT137831 in diabetic nephropathy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.